EIF2S1 and Miyoshi myopathy: This hypothesis is in agreement with recent studies conducted on MM cells showing that amplifying the intensity of the UPR by combining the proteasome inhibitor Bortezomib with a calcium channel blocker [33] or with a mimetic of phosphorylated eIF-2 alpha [34] tips the UPR balance from survival to death.